The raised guidance and strong Q1 beat (especially on GAAP EPS) should drive positive momentum. Watch for continued organic growth in Diagnostics (3.1% organic) and Central Labs (11.3% growth). The $8.64B backlog (+5.6% YoY) provides visibility into Biopharma revenue. Monitor upcoming acquisitions and the new Central Lab facility investment.
Price Chart
Executive Summary
Labcorp reported Q1 2026 revenue of $3.54B (+5.8% YoY) and diluted GAAP EPS of $3.35 (+32.8% YoY), beating consensus estimates. The company raised its full-year 2026 Adjusted EPS guidance to $17.70-$18.35 (up $0.13 at the midpoint) and enterprise revenue growth guidance to 5.0%-6.1%. Strong operational performance across both Diagnostics and Biopharma segments, coupled with raised guidance, signals accelerating momentum.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $3.54B, up 5.8% YoY from $3.35B
- Diluted GAAP EPS of $3.35, up 32.8% YoY from $2.52
- Adjusted EPS of $4.25, up 10.6% YoY from $3.84
- Raised FY2026 Adjusted EPS guidance to $17.70-$18.35 (prior $17.55-$18.25)
- Raised FY2026 enterprise revenue growth guidance to 5.0%-6.1% (prior 4.7%-6.0%)
- Diagnostics segment revenue $2.76B (+5.0% YoY), AOI margin 16.6% (+30bps)
- Biopharma segment revenue $780.6M (+8.2% YoY), AOI margin 15.5% (+60bps)
- Free cash flow of $70.5M vs -$107.5M in prior year quarter
- Backlog of $8.64B, up 5.6% YoY
- Repurchased $98M of stock and paid $61.2M in dividends in Q1
Financial Impact
Raised FY2026 Adjusted EPS midpoint by $0.13 to $18.03, revenue midpoint increased by ~$25M to $14.725B
Risk Factors
- Organic revenue growth of 3.1% is modest and below total reported growth of 5.8%
- Total debt increased to $6.33B from $5.58B at year-end due to debt pre-funding
- Accounts receivable increased $187.9M, pressuring working capital
- Adverse weather impacted organic volume growth (1.1% vs 1.8% price/mix)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000920148-26-000135 |
| Document: lh-20260430.htm | 0000920148-26-000135 |
| Document: 0000920148-26-000135-index-headers.html | 0000920148-26-000135 |
| Document: 0000920148-26-000135-index.html | 0000920148-26-000135 |
| Document: 0000920148-26-000135.txt | 0000920148-26-000135 |
| 8-K Data (Synthetic) | 0000920148-26-000135 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $311.54 $320.71 | ▲ +2.94% | ▲ +3.16% | $308.49 (−0.98%) |
Aug 28, 2026 5w ago | 8-K | $335.11 $326.89 | ▼ −2.45% | ▼ −2.56% | $308.49 (−7.94%) |
Aug 18, 2026 6w ago | Insider Cluster | $322.18 $337.68 | ▲ +4.81% | ▲ +5.01% | $308.49 (−4.25%) |
Aug 17, 2026 6w ago | 8-K | $323.34 $339.34 | ▲ +4.95% | ▲ +6.14% | $308.49 (−4.59%) |
Aug 14, 2026 7w ago | 8-K | $318.13 $336.34 | ▲ +5.72% | ▲ +7.09% | $308.49 (−3.03%) |
Aug 12, 2026 7w ago | Insider Cluster | $323.48 $330.44 | ▲ +2.15% | ▲ +2.60% | $308.49 (−4.63%) |
Aug 6, 2026 8w ago | Insider Cluster | $316.53 $322.59 | ▲ +1.91% | ▲ +0.70% | $308.49 (−2.54%) |
Jul 30, 2026 9w ago | 8-K | $315.53 $316.53 | ▲ +0.32% | ▼ −3.31% | $308.49 (−2.23%) |
Jul 10, 2026 12w ago | 8-K | $276.81 $281.94 | ▲ +1.85% | ▲ +2.41% | $308.49 (+11.44%) |
Jun 30, 2026 13w ago | 8-K | $283.88 $283.86 | ▼ −0.01% | ▼ −0.27% | $308.49 (+8.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access